摘要
目的:研究匹多莫德联合孟鲁司特钠治疗毛细支气管炎的效果和对患者不良反应的影响。方法:选取本院2019年5月-2020年5月期间收治的毛细支气管炎患儿96例,随机分为研究组和对照组,每组48例,研究组采用匹多莫德联合孟鲁司特钠治疗,对照组仅使用孟鲁司特钠治疗。观察并比较两组患者的治疗效果、不良反应、体征改善情况、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)指标及白介素-4(IL-4)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平。结果:研究组治疗总有效率显著高于对照组(P<0.05);研究组不良反应总发生率显著低于对照组(P<0.05);研究组的症状改善时间均短于对照组(P<0.05);研究组治疗后的CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)等免疫指标显著优于对照组(P<0.05);研究组治疗后IL-4、IL-6、TNF-α等炎症指标显著优于对照组(P<0.05)。结论:对毛细支气管炎患者采取匹多莫德联合孟鲁司特钠治疗,能够减少不良反应,提升免疫功能,强化抗感染能力,抑制炎症,缩短体征改善时间,治疗效果较好。
Objective:To study the effect of Pidotimod combined with Montelukast Sodium in the treatment of bronchiolitis and its influence on patients’adverse reactions.Method:A total of 96 children with bronchiolitis admitted to our hospital from May 2019 to May 2020 were selected and randomly divided into study group and control group,48 cases in each group.The study group was given Pidotimod combined with Montelukast Sodium,the control group was given Montelukast Sodium.The treatment effects,adverse reactions,improvement of signs,CD4^(+),CD8^(+),CD4^(+)/CD8^(+)indicators and interleukin-4(IL-4),interleukin-6(IL-6)The level of tumor necrosis factor-α(TNF-α)of two groups were observed and compared.Result:The total effective rate of treatment in the study group was significantly higher than that in the control group(P<0.05);the total incidence of adverse reactions in the study group was significantly lower than that in the control group(P<0.05);the symptom improvement time of the study group was shorter than that in the control group(P<0.05).After treatment,the immune indexes of CD4^(+),CD8^(+),CD4^(+)/CD8^(+)in the study group were significantly better than those in the control group(P<0.05).After treatment,the study group had significantly better inflammatory indexes such as IL-4,IL-6,TNF-αIn the control group(P<0.05).Conclusion:Pidotimod combined with Montelukast Sodium treatment for patients with bronchiolitis can reduce adverse reactions,improve immune function,strengthen anti-infection ability,inhibit inflammation,shorten the time for improvement of physical signs,and the treatment effect is better.
作者
唐国民
漆红艳
TANG Guomin;QI Hongyan(Shayang County People’s Hospital,Shayang 448200,China;不详)
出处
《中国医学创新》
CAS
2021年第4期45-48,共4页
Medical Innovation of China
基金
湖北省恩施州医疗卫生类指导性项目(XYJ2019000055)。